AUB ScholarWorks

Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration

Show simple item record

dc.contributor.author Bashshur Z.F.
dc.contributor.author Schakal A.R.
dc.contributor.author El-Mollayess G.M.
dc.contributor.author Arafat S.
dc.contributor.author Jaafar D.
dc.contributor.author Salti H.I.
dc.contributor.editor
dc.date Apr-2011
dc.date.accessioned 2017-10-05T15:49:21Z
dc.date.available 2017-10-05T15:49:21Z
dc.date.issued 2011
dc.identifier 10.1097/IAE.0b013e3181fe54ab
dc.identifier.isbn
dc.identifier.issn
dc.identifier.uri http://hdl.handle.net/10938/18806
dc.description.abstract Purpose: To compare verteporfin photodynamic therapy combined with intravitreal ranibizumab (combination therapy) versus ranibizumab monotherapy for management of neovascular age-related macular degeneration. Methods: Thirty patients (40 eyes) with neovascular age-related macular degeneration were prospectively allocated to combination therapy or monotherapy. In monotherapy, the induction phase consisted of 3 consecutive monthly ranibizumab injections (0.5 mg), while the combination therapy had a single session of photodynamic therapy with intravitreal ranibizumab. Follow-up treatment for either group consisted only of additional as-needed ranibizumab injections. The main outcome measure was that a proportion of eyes losing 15 letters of visual acuity after 12 months. Results: Except for 1 eye in combination therapy, all eyes in both groups lost 15 letters of visual acuity. At 12 months, there was a mean gain of +12 letters and +3.2 letters for monotherapy and combination therapy, respectively (relative percent change of 32percent vs. 7percent, P = 0.03). Anatomical improvement was similar in both groups. After induction, the time until ranibizumab retreatment was longer for combination therapy (P = 0.002) while ranibizumab injections were required more frequently with monotherapy (P = 0.015). Conclusion: Ranibizumab monotherapy showed greater improvement in visual acuity versus combination therapy. However, combination therapy required fewer ranibizumab injections. Larger trials need to confirm the findings of this pilot study. © The Ophthalmic Communications Society, Inc.
dc.format.extent
dc.format.extent Pages: (636-644)
dc.language English
dc.publisher PHILADELPHIA
dc.relation.ispartof Publication Name: Retina; Publication Year: 2011; Volume: 31; no. 4; Pages: (636-644);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration
dc.type Article
dc.contributor.affiliation Bashshur, Z.F., Department of Ophthalmology, American University of Beirut, Medical Center, P.O. Box 11-0236-B11, Beirut, Lebanon
dc.contributor.affiliation Schakal, A.R., Department of Ophthalmology, American University of Beirut, Medical Center, P.O. Box 11-0236-B11, Beirut, Lebanon, Department of Ophthalmology, Hotel Dieu de France, St. Joseph University, Beirut, Lebanon
dc.contributor.affiliation El-Mollayess, G.M., Department of Ophthalmology, American University of Beirut, Medical Center, P.O. Box 11-0236-B11, Beirut, Lebanon
dc.contributor.affiliation Arafat, S., Department of Ophthalmology, American University of Beirut, Medical Center, P.O. Box 11-0236-B11, Beirut, Lebanon
dc.contributor.affiliation Jaafar, D., Department of Ophthalmology, American University of Beirut, Medical Center, P.O. Box 11-0236-B11, Beirut, Lebanon
dc.contributor.affiliation Salti, H.I., Department of Ophthalmology, American University of Beirut, Medical Center, P.O. Box 11-0236-B11, Beirut, Lebanon
dc.contributor.authorAddress Bashshur, Z. F.; Department of Ophthalmology, American University of Beirut, Medical Center, P.O. Box 11-0236-B11, Beirut, Lebanon; email: zb00@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Ophthalmology;
dc.contributor.authorDepartment Ophthalmology
dc.contributor.authorDivision
dc.contributor.authorEmail zb00@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Bashshur, ZF
dc.contributor.authorInitials Schakal, AR
dc.contributor.authorInitials El-Mollayess, GM
dc.contributor.authorInitials Arafat, S
dc.contributor.authorInitials Jaafar, D
dc.contributor.authorInitials Salti, HI
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Bashshur, ZF (reprint author), Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236-B11, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016-j.ajo.2003.11.059; Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097-IAE.0b013e3180323de7; Azab M, 2004, RETINA-J RET VIT DIS, V24, P1; Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448; Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097-IAE.0b013e3181a46a8a; Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097-00004397-200404430-00005; Arnold J, 2001, AM J OPHTHALMOL, V131, P541; Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056-NEJMoa062655; CONNOLLY BP, 2007, INVEST OPHTH VIS SCI, V48, P4555; Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007-s10384-008-0551-9; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016-j.ajo.2007.12.029; Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016-j.ajo.2007.01.028; Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097-IAE.0b013e318042b53f; Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016-j.ophtha.2005.10.052; Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322; Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185-030079907X167624; Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016-j.ophtha.2008.12.057; Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167-iovs.08-1689; Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136-bjo.2007.135335; Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1132, DOI 10.1097-IAE.0b013e318170d76d; Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016-j.ajo.2009.01.024; MCNEIL R, ANTI VEGF THERAPY NE; Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167-iovs.02-0604; Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352; *OPTH TIM STAFF RE, RAD STUD SHOWS POS 1; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056-NEJMoa054481; Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136-bjo.2008.137885; Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016-j.preteyeres.2009.01.001; Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835; Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136-bjo.2007.135277; Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097-IAE.0b013e3181960a28; SLAKTER JS, 2007, INVEST OPHTHALMOL VI, V48; Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097-IAE.0b013e3181b1bb06; Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097-IAE.0b013e318042d3b0; Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
dc.description.citedCount 7
dc.description.citedTotWOSCount 8
dc.description.citedWOSCount 6
dc.format.extentCount 9
dc.identifier.articleNo
dc.identifier.coden RETID
dc.identifier.pubmedID 21124254
dc.identifier.scopusID 79955060859
dc.identifier.url
dc.publisher.address 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Retin.-J. Retin. Vitr. Dis.
dc.relation.ispartOfIssue 4
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Retina
dc.relation.ispartofPubTitleAbbr Retina
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 31
dc.source.ID WOS:000288783200002
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS ranibizumab, 347396-82-1
dc.subject.otherChemCAS verteporfin, 129497-78-5
dc.subject.otherChemCAS Antibodies, Monoclonal, Humanized
dc.subject.otherChemCAS Photosensitizing Agents
dc.subject.otherChemCAS Porphyrins
dc.subject.otherChemCAS ranibizumab
dc.subject.otherChemCAS verteporfin, 129497-78-5
dc.subject.otherIndex ranibizumab
dc.subject.otherIndex verteporfin
dc.subject.otherIndex aged
dc.subject.otherIndex article
dc.subject.otherIndex cataract
dc.subject.otherIndex cataract extraction
dc.subject.otherIndex clinical article
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex drug safety
dc.subject.otherIndex female
dc.subject.otherIndex follow up
dc.subject.otherIndex human
dc.subject.otherIndex lens implant
dc.subject.otherIndex male
dc.subject.otherIndex monotherapy
dc.subject.otherIndex photodynamic therapy
dc.subject.otherIndex prospective study
dc.subject.otherIndex retina hemorrhage
dc.subject.otherIndex retina macula age related degeneration
dc.subject.otherIndex retina tear
dc.subject.otherIndex side effect
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex visual acuity
dc.subject.otherIndex Aged
dc.subject.otherIndex Antibodies, Monoclonal, Humanized
dc.subject.otherIndex Combined Modality Therapy
dc.subject.otherIndex Female
dc.subject.otherIndex Fluorescein Angiography
dc.subject.otherIndex Humans
dc.subject.otherIndex Intravitreal Injections
dc.subject.otherIndex Male
dc.subject.otherIndex Photochemotherapy
dc.subject.otherIndex Photosensitizing Agents
dc.subject.otherIndex Porphyrins
dc.subject.otherIndex Prospective Studies
dc.subject.otherIndex Retina
dc.subject.otherIndex Retreatment
dc.subject.otherIndex Time Factors
dc.subject.otherIndex Tomography, Optical Coherence
dc.subject.otherIndex Treatment Outcome
dc.subject.otherIndex Visual Acuity
dc.subject.otherIndex Wet Macular Degeneration
dc.subject.otherKeywordPlus SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
dc.subject.otherKeywordPlus RANDOMIZED CLINICAL-TRIALS
dc.subject.otherKeywordPlus OPTICAL COHERENCE TOMOGRAPHY
dc.subject.otherKeywordPlus INTRAVITREAL BEVACIZUMAB
dc.subject.otherKeywordPlus TRIPLE THERAPY
dc.subject.otherKeywordPlus COMBINATION
dc.subject.otherKeywordPlus TAP
dc.subject.otherKeywordPlus DEXAMETHASONE
dc.subject.otherWOS Ophthalmology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account